AL-ADTRAN
25.3.2024 14:01:34 CET | Business Wire | Press release
Adtran and Vertilas today announced the industry’s first 100Gbit/s PAM4 single-mode vertical-cavity surface-emitting laser (VCSEL) technology with capabilities up to 1.6Tbit/s. On display at this week’s OFC, it sets new standards for low power consumption in optical engines and modules, with up to 80% reduction in power on the transmit optics compared to conventional solutions. Tailored specifically for the rigorous demands of intra-data center operations and AI/ML workloads, Adtran’s latest offering achieves unprecedented efficiency, consuming less than 2pJ/bit, including the laser driver. This significantly undercuts current industry standards, including those cited by co-packaged optics. The advancement is set to extend the capabilities of Adtran’s MicroMux™ family of small-form-factor pluggable transceivers. A major step towards meeting the needs of the rapidly expanding generative AI application market, Adtran’s latest innovation addresses the growing demand for robust, high-capacity and environmentally friendly data processing solutions.
“As the importance of data volume and speed escalates, the demand for increased bandwidth and enhanced energy efficiency accelerates. Our introduction of the market’s first 100Gbit/s PAM4 single-mode VCSEL technology, scalable to 1.6Tbit/s, epitomizes our proactive approach to tackling these emerging requirements. By pushing the limits of speed and significantly reducing power consumption, we’re creating tomorrow’s benchmarks,” said Ross Saunders, GM of optical engines at Adtran. “Our new technology promises to significantly improve intra-data center connectivity and AI application efficiencies, merging high performance with long-term sustainability. As we prepare for the leap towards 800Gbit/s and 1.6Tbit/s applications, we’re enhancing the foundations of efficient, high-capacity data ecosystems worldwide.”
Building on the success of Adtran’s MicroMux™ family, the new VCSEL technology leverages a short-cavity single-mode design and is based on indium phosphide semiconductor material. This enables it to operate across both O-band and C-band wavelengths, delivering 100Gbit/s per channel. By stacking multiple single-mode lasers into arrays, this approach achieves throughput of 800Gbit/s and 1.6Tbit/s, ensuring superior performance with a significant reduction in power consumption and costs. This enhanced energy efficiency presents a major advantage for IP router and Ethernet switch faceplate density. What’s more, its versatility extends to supporting a wide array of applications from DR4/8/16 to various FR4 links within optical engines, all while maintaining power consumption below 200mW per lane.
“As applications such as generative AI proliferate and enterprises expand their AI clusters, the need for advanced optical interconnects capable of supporting Terabit connectivity has reached a critical juncture. Our 100Gbit/s PAM4 single-mode VCSEL technology meets this challenge head-on. It enables energy efficiency and the capacity for higher-density deployments while at the same time addressing manufacturing, testing and assembly costs,” commented Christoph Glingener, CTO of Adtran. “This technology supports throughput of up to 800Gbit/s and 1.6Tbit/s, significantly reducing operational expenses while enhancing network capabilities. Our approach underscores a commitment to delivering sustainable, high-capacity networking solutions that break through existing barriers, readying networks for the next wave of AI infrastructure development.”
Demos of Adtran’s new VCSEL technology are available at this week’s OFC on request.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240322173283/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
